You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.
UK-NOTPR-1010 | April 2022
Lundbeck publishes the results from our research and clinical studies in scientific journals and
presents these results at scientific conferences. Lundbeck also discloses clinical trial information and results summaries in public registries and shares clinical data. The Lundbeck policy for scientific publications and responsible clinical trial data sharing covers all scientific publications authored by Lundbeck and clinical trial data sharing for trials sponsored by H.
In accordance with The Association of the British Pharmaceutical Industry (ABPI), Lundbeck UK will disclose details of clinical trials in accordance with the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases and the Joint Position on the Publication of Clinical Trial Results in Scientific Literature.
Lundbeck publishes the results from clinical studies of its products and drug development candidates, irrespective of whether the results are positive or negative, and acknowledges a special obligation to publish data related to patient safety.
As per current Good Publication Practice, Lundbeck will submit for publication, the results of
Lundbeck-sponsored clinical studies, primarily in peer-reviewed journals, or as abstracts, posters, or other presentations at scientific meetings. Lundbeck will publish through open access journals wherever possible.
Publication activities will be undertaken responsibly and ethically to ensure that all relevant
information is communicated clearly and in a timely manner. Wherever possible, manuscripts will be submitted no later than 18 months after study completion for approved products. Our commitment to publish also applies to drug development compounds for which development has been discontinued. In situations where the data is of limited scientific or clinical value, or in the case of multiple journal rejections, posting results on a public clinical trial registry site may be an option for disclosure.
Lundbeck encourages publication of the results from drug discovery. The timing of nonclinical
publications will take into consideration intellectual property rights as well as legislation and national practices in patent law.
When entering into research and development collaborations, it is Lundbeck’s commitment to maintain ethical and transparent publication practices, which is in accordance with Good Publication Practice
Lundbeck will prepare clinical publications in accordance with the guidelines established by the International Committee of Medical Journal Editors (ICMJE).
To protect intellectual property rights, any collaboration between Lundbeck and a third party will be subject to a formal agreement that will address ownership of and access to data. All authors of a Lundbeck-sponsored publication will be provided with a copy of the final protocol, statistical analysis plan, and clinical study report, including the statistical tables and figures that are needed to prepare the planned publication and, on request, will be provided access to the clinical study data.
Lundbeck is committed to ensuring that authorship for all publications complies with the criteria developed by the ICMJE. Lundbeck bases authorship credit on the following criteria:
Lundbeck may employ professional writers to assist in producing publications and presentations. Care will be taken to ensure any such assistance follows ethically acceptable practice by ensuring that:
Lundbeck supports the need for all authors of publications to disclose any potential conflicts of interest, including any financial relationships that might be perceived to bias their work.
Authors are not paid for authorship, but material support, for example professional medical writing assistance may be offered.
Lundbeck is committed to responsible sharing of clinical trial data in a manner that is consistent with: safeguarding the privacy of patients, respecting the integrity of national regulatory systems and protecting the intellectual property of the sponsor.
As a pharmaceutical company, Lundbeck considers the sharing of information from company-sponsored clinical trials to be an important part of fulfilling our mission to improve quality of life for patients. The sharing of clinical trial information will enable the medical and scientific community in the further understanding of the diseases and their treatment for the future benefit of patients.
Researchers may identify studies relevant for their research proposal by searching public registries such as www.clinicaltrials.gov or www.clinicaltrialsregister.eu.
Lundbeck has developed some of the most widely prescribed therapies for brain diseases.
We pursue our business purpose guided by several pillars and our Code of Conduct.
We strive for Progress in Mind - our multifaceted approach to patients.
UK-NOTPR-0548 | April 2022